This amounts, in fact, to excluding almost any prescription of Xevudy, a synthetic antibody developed by the British GSK, because BA.2 now represents the overwhelming majority of coronavirus contaminations. There is in France an “almost exclusive circulation of the BA.2 sub-lineage”, noted the French public health agency on Friday in its weekly update.
For severe forms
Administered intravenously, Xevudy, which is intended for people recently infected with the coronavirus and at risk of a severe form, had nevertheless proved to be one of the only treatments to remain effective against the Omicron variant when it arrived at the end of 2021. But, since then, the previous dominant version of Omicron, BA.1, has been supplanted by BA.2, against which this treatment is far less effective.